Part II: Cancer in Indigenous Africans-causes and control

The Lancet Oncology

Volumn 9, Issue 8, 2008, Pages 786-795

  Sitas, Freddy ^a   Parkin, D Max ^b   Chirenje, Mike ^c   Stein, Lara ^d   Abratt, Raymond ^e   Wabinga, Henry ^f  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; HEPATITIS B VACCINE; WART VIRUS VACCINE;

AFRICA; BACTERIUM; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENESIS; COST EFFECTIVENESS ANALYSIS; ESOPHAGUS CANCER; GENETIC VARIABILITY; HUMAN; INDIGENOUS PEOPLE; KAPOSI SARCOMA; LIFESTYLE; LIVER CANCER; MALARIA CONTROL; NONHODGKIN LYMPHOMA; PARASITE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SCHISTOSOMIASIS; STOMACH CANCER; TOBACCO; UTERINE CERVIX CANCER; VIRUS; VIRUS CARCINOGENESIS;

ADULT; AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE DISTRIBUTION; AGED; DEVELOPING COUNTRIES; FEMALE; HEALTH SERVICES, INDIGENOUS; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; POVERTY; PRIMARY PREVENTION; RISK ASSESSMENT; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS;

EID: 47849124880     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70198-0     Document Type: Review

References (86)

1. Parkin D., Sitas F., Chirenje M., Stein L., Abratt R., and Wabinga H. Part I: Cancer in Indigenous Africans-burden, distribution, and trends. Lancet Oncol 9 (2007) 683-692
2. Cavalli-Sforza L. Genes, peoples, and languages. Proc Natl Acad Sci USA 94 (1997) 7719-7724
3. Matthews E. Global vegetation and land use: new high resolution data bases for climate studies. J Clim Appl Meteorol 22 (1983) 474-487
4. Clifford G., Franceschi S., Diaz M., Munoz N., and Villa L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 suppl 3 (2006) S26-S34
5. Smith J., Bosetti C., Munoz N., et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 111 (2004) 431-439
6. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet 370 (2007) 1609-1621
7. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 118 (2006) 1481-1495
8. Parkin D., Ferlay J., Hamdi-Cherif M., et al. Cancer in Africa: epidemiology and prevention (2003), IARC Scientific Publications, Lyon 1-414
9. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm (accessed June 25, 2008).
10. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet 353 (1999) 869-873
11. Miller A. Cervical cancer screening programmes. Managerial guidelines (1992), World Health Organization, Geneva
12. Chirenje Z., Rusakaniko S., Akino V., and Mlingo M. A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia. J Obstet Gynaecol 21 (2001) 617-621
13. Sankaranarayanan R., Esmy P., Rajkumar R., et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370 (2007) 398-406
14. Sankaranarayanan R., Basu P., Wesley R., et al. Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa. Int J Cancer 110 (2004) 907-913
15. Rosenberg L., Kelly J., Shapiro S., Hoffman M., and Cooper D. Risk factors for breast cancer in South African women. S Afr Med J 92 (2002) 447-448
16. Okobia M., Bunker C., Zmuda J., et al. Case-control study of risk factors for breast cancer in Nigerian women. Int J Cancer 119 (2006) 2179-2185
17. Olopade O., Fackenthal J., Dunston G., Tainsky M., Collins F., and Whitfield-Broome C. Breast cancer genetics in African Americans. Cancer 97 (2003) 236-245
18. Colditz G., Baer H., and Tamimi R. Breast Cancer. In: Schottenfeld D., and Fraumeni J. (Eds). Cancer epidemiology and prevention (2006), Oxford University Press, New York
19. Adebamowo C., and Adekunle O. Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg 86 (1999) 665-668
20. Shapiro S., Rosenberg L., Hoffman M., et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 151 (2000) 396-403
21. Baquet C., and Commiskey P. Socioeconomic factors and breast carcinoma in multicultural women. Cancer 88 (2000) 1256-1264
22. Adebamowo C., Hu F., Cho E., Spiegelman D., Holmes M., and Willett W. Dietary patterns and the risk of breast cancer. Ann Epidemiol 15 (2005) 789-795
23. Calle E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (2004) 579-591
24. Adebamowo C., Ogundiran T., Adenipekun A., et al. Waist-hip ratio and breast cancer risk in urbanized Nigerian women. Breast Cancer Res 5 (2003) R18-R24
25. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 360 (2002) 187-195
26. Coogan P., Rosenberg L., Shapiro S., and Hoffman M. Lactation and breast carcinoma risk in a South African population. Cancer 86 (1999) 982-989
27. Smith R., Caleffi M., Albert U., et al. Breast cancer in limited-resource countries: early detection and access to care. Breast J 12 suppl 1 (2006) S16-S26
28. Boulos S., Gadallah M., Neguib S., et al. Breast screening in the emerging world: high prevalence of breast cancer in Cairo. Breast 14 (2005) 340-346
29. From the Centers for Disease Control and prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 269 (1993) 729-730
30. Serraino D., Pezzotti P., Dorrucci M., Alliegro M., Sinicco A., and Rezza G. Cancer incidence in a cohort of human immunodeficiency virus seroconverters. HIV Italian Seroconversion Study Group. Cancer 79 (1997) 1004-1008
31. Sitas F., Carrara H., Beral V., et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med 340 (1999) 1863-1871
32. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92 (2000) 1823-1830
33. Parkin D. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118 (2006) 3030-3044
34. Madhava V., Burgess C., and Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2 (2002) 293-302
35. Edmunds W., Medley G., Nokes D., Hall A., and Whittle H. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 253 (1993) 197-201
36. Kirk G., Lesi O., Mendy M., et al. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39 (2004) 211-219
37. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 82. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene (2002), International Agency for Research on Cancer, Lyon
38. Qian G., Ross R., Yu M., et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3 (1994) 3-10
39. Montesano R., Hainaut P., and Wild C. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 89 (1997) 1844-1851
40. Kirk G., Bah E., and Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis 27 (2006) 2070-2082
41. Mandishona E., MacPhail A., Gordeuk V., et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 27 (1998) 1563-1566
42. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 83. Tobacco smoke and involuntary smoking (2004), International Agency for Research on Cancer, Lyon
43. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 72. Hormonal contraception and post-meonpausal hormonal therapy Vol 72 (1999), International Agency for Research on Cancer, Lyon
44. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 44. Alcohol drinking (1988), International Agency for Research on Cancer, Lyon
45. Mohamed A., Kew M., and Groeneveld H. Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern African blacks. Int J Cancer 51 (1992) 537-541
46. Viviani S., Jack A., Hall A., et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17 (1999) 2946-2950
47. Chang M., Chen C., Lai M., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 (1997) 1855-1859
48. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. http://www.who.int/immunization_monitoring/en/ (accessed June 25, 2008).
49. Wild C., and Hall A. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 462 (2000) 381-393
50. Turner P., Sylla A., Gong Y., et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet 365 (2005) 1950-1956
51. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 67. Human immunodeficiency viruses and human T-cell lymphotropic viruses (1996), International Agency for Research on Cancer, Lyon 1-424
52. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 70. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8 (1997), International Agency for Research on Cancer, Lyon
53. Remick S. Acquired immunodeficiency syndrome-related non-Hodgkin lymphoma. Cancer Control 2 (1995) 97-103
54. Schulz T., Boshoff C., and Weiss R. HIV infection and neoplasia. Lancet 348 (1996) 587-591
55. Chokunonga E., Levy L., Bassett M., et al. Aids and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS 13 (1999) 2583-2588
56. Parkin D., Wabinga H., Nambooze S., and Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 13 (1999) 2563-2570
57. Burkitt D. Etiology of Burkitt's lymphoma-an alternative hypothesis to a vectored virus. J Natl Cancer Inst 42 (1969) 19-28
58. Rainey J., Omenah D., Sumba P., Moormann A., Rochford R., and Wilson M. Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. Int J Cancer 120 (2007) 121-127
59. van den Bosch C. Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter?. Lancet Oncol 5 (2004) 738-746
60. Geser A., de Thé G., Lenoir G., Day N., and Williams E. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int J Cancer 29 (1982) 397-400
61. Rochford R., Cannon M., and Moormann A. Endemic Burkitt's lymphoma: a polymicrobial disease?. Nat Rev Microbiol 3 (2005) 182-187
62. Carpenter L., Newton R., Casabonne D., et al. Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. Int J Cancer 122 (2008) 1319-1323
63. Geser A., Brubaker G., and Draper C. Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma. Am J Epidemiol 129 (1989) 740-752
64. Ojesina A., Akang E., and Ojemakinde K. Decline in the frequency of Burkitt's lymphoma relative to other childhood malignancies in Ibadan, Nigeria. Ann Trop Paediatr 22 (2002) 159-163
65. Sitas F., Pacella-Norman R., Carrara H., et al. The spectrum of HIV-1 related cancers in South Africa. Int J Cancer 88 (2000) 489-492
66. Ross R., Pike M., Coetzee G., et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58 (1998) 4497-4504
67. Delongchamps N., Singh A., and Haas G. Epidemiology of prostate cancer in Africa: another step in the understanding of the disease?. Curr Probl Cancer 31 (2007) 226-236
68. Hayes R., Pottern L., Strickler H., et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 82 (2000) 718-725
69. de Gonzalez A.B., Urban M., Sitas F., et al. Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: a case control study. Infect Agent Cancer 1 (2006) 2
70. Sitas F., Urban M., Stein L., et al. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer 2 (2007) 6
71. Walker A., Walker B., Tsotetsi N., Sebitso C., Siwedi D., and Walker A. Case-control study of prostate cancer in black patients in Soweto, South Africa. Br J Cancer 65 (1992) 438-441
72. Signorello L., and Adami H. Prostate cancer. In: Adami H., Hunter D., and Trichopoulos D. (Eds). Textbook of cancer epidemiology. Monographs in epidemiology and biostatistics (2002), Oxford University Press, New York
73. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 61. Schistosomes, liver flukes and Helicobacter pylori (1994), International Agency for Research on Cancer, Lyon
74. Mitchell H., Ally R., Wadee A., Wiseman M., and Segal I. Major differences in the IgG subclass response to Helicobacter pylori in the first and third worlds. Scand J Gastroenterol 37 (2002) 517-522
75. Kidd M., Lastovica A., Atherton J., and Louw J. Heterogeneity in the Helicobacter pylori vacA and cagA genes: association with gastroduodenal disease in South Africa?. Gut 45 (1999) 499-502
76. Mbulaiteye S., Gold B., Pfeiffer R., et al. H pylori-infection and antibody immune response in a rural Tanzanian population. Infect Agent Cancer 1 (2006) 3
77. Kogevinas M., and Trichopoulos D. Urinary bladder cancer. In: Adami H., Hunter D., and Trichopoulos D. (Eds). Textbook of cancer epidemiology. Monographs in epidemiology and biostatistics (2002), Oxford University Press, New York
78. Sitas F., Parkin M., Chirenje Z., Stein L., Mqoqi N., and Wabinga H. Cancers. In: Jamison D., Feachem R., Makgoba M., et al. (Eds). Disease in sub-Saharan Africa (2006), The World Bank, Washington DC
79. World Health Organization (WHO). Tobacco or health: a global status report (1997), World Health Organisation, Geneva
80. Sitas F., Urban M., Bradshaw D., Kielkowski D., Bah S., and Peto R. Tobacco attributable deaths in South Africa. Tob Control 13 (2004) 396-399
81. Saloojee Y. Tobacco control in South Africa. Chronic diseases of lifestyle in South Africa since 1995-2005. Technical report (2006), South African Medical Research Council, Tygerberg
82. Gondos A., Brenner H., Wabinga H., and Parkin D. Cancer survival in Kampala, Uganda. Br J Cancer 92 (2005) 1808-1812
83. Barton M., Frommer M., and Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol 7 (2006) 584-595
84. Pain & Policy Studies Group. Availability of morphine and pethidine in the world and Africa, with a special focus on: Botswana, Ethiopia, Kenya, Malawi, Nigeria, Rwanda, Tanzania, Zambia. http://www.medsch.wisc.edu/painpolicy/publicat/monograp/africa06.pdf (accessed June 25, 2008).
85. Cape Town Declaration of Cancer Contorl in Africa. http://www.iaea.org/NewsCenter/News/PDF/ctdeclaration1206.pdf (accessed June 25, 2008).
86. In: Sloan F., and Gelband H. (Eds). Cancer control opportunities in low and middle-income countries (2007), The National Academies Press, Washington, DC